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While clinical disease caused by drug-sensitive 
Mycobacterium tuberculosis (MTB) can usually be 
treated successfully, clinical disease caused by drug-
insensitive MTB is associated with a poorer prognosis. 
In December 2012, a new drug, bedaquiline, was 
approved by the US Food and Drug Administration (FDA) for the 
treatment of multidrug-resistant (MDR) tuberculosis (TB). In a review 
paper, the four goals of a compassionate use/early access programme 
for new TB drugs are outlined: to protect patients; to minimise the risk 
of treatment failure and emergence of resistance; to exercise fairness; 
and to comply with regulatory guidance.[1] This article documents 
the process whereby the National Department of Health (NDoH), 
Right to Care (a US Agency for International Development-funded 
non-governmental organisation) and Médecins Sans Frontières (MSF) 
obtained access to this medication for South Africans who might 
benefit from subsequent implementation of the Clinical Access to 
Bedaquiline Programme (CAP). Attention was paid to the regulatory 
framework, fairness and protection of patients while being cognisant of 
the need to prevent emergence of resistance to bedaquiline. 
Setting
In South Africa (SA), 14 161 cases of MDR-TB were documented in 
2012. The proportion of MDR-TB cases with additional resistance 
to a quinolone and a second-line injectable, i.e. extensively drug 
resistant TB (XDR-TB), is estimated at 10.9% (N=1  545)[2] with an 
ill-defined proportion being ‘pre-XDR-TB’, i.e. MDR with resistance 
to either a quinolone or a second-line injectable. While the outcomes 
of patients with pre-XDR-TB have not been well documented, the 
outcomes of XDR-TB are poor. In a retrospective cohort study at four 
designated XDR-TB provincial treatment facilities in SA between 
August 2002 and February 2008, 195 adult patients with culture-
proven XDR-TB were analysed; 21 patients died before initiation of 
any treatment, 174 patients (82 with HIV infection) were treated, and 
62 (36%) patients died during follow-up. Sputum culture conversion 
was achieved in only 33/174 (19%) patients.[3]
There are several new classes of TB drugs becoming available, 
including bedaquiline, which is a diarylquinoline. Bedaquiline 
offers a new mechanism of anti-TB action by specifically inhibiting 
mycobacterial adenosine triphosphate synthase.[4] In December 2012, 
the FDA granted accelerated approval for bedaquiline based on two 
phase 2 studies involving 440 people with drug-resistant TB (DR-TB). 
The first trial was a randomised, double-blind, placebo-controlled trial 
with bedaquiline and an optimised background regimen. The second 
was an open-label trial. Bedaquiline, when given with other existing 
MDR-TB drugs, increased the proportion of people whose sputum 
cultures converted to negative after 2 and 6 months of treatment. 
Bedaquiline, when given with other existing MDR-TB drugs, also 
reduced the time to sputum culture conversion, offering the possibility 
of a shorter treatment duration in the future. Bedaquiline is currently 
only commercially available in the US and is not yet registered by the 
SA Medicines Control Council (MCC). In the interim, some patients 
with few other treatment options, and before the drug’s approval in 
their countries, have been offered bedaquiline through an early access 
programme put in place by the manufacturer, Janssen Pharmaceutica. 
Under controlled compassionate use programmes and early access 
trials, several countries including SA have made bedaquiline available 
for patients with XDR- or pre-XDR-TB. In an expanded access 
programme (EAP) model, a clinician requests a drug for a named 
individual patient based on a specific clinical access guidance 
document. In an EAP, patients can be enrolled and offered access to 
the medication if they meet specific eligibility criteria. Based on this 
model, MDR-TB patients who have limited treatment options have 
been allowed access to bedaquiline as part of an individually tailored 
treatment regimen in a CAP in SA.
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Key aspects of the CAP
Exercise of fairness
SA has nine provinces, all having MDR-/XDR-TB treatment facilities 
but with differing MDR-/XDR-TB burdens (Table 1). According to 
the National Health Laboratory Service, in KwaZulu-Natal, 11  393 
diagnoses of MDR-TB were made between 2004 and 2010 and in the 
same time period 782 diagnoses were made in Limpopo. 
To ensure equitable access to bedaquiline by selected XDR- or 
pre-XDR-TB patients, there should ideally be a clinical site in each 
province offering the programme.
Initially, four sites were approved by the MCC to begin the 
programme, based on results of clinical research. However, this 
excluded other, less well-resourced provinces. Additional sites in all 
the remaining provinces have since been identified for expansion of 
the project. 
To prepare all future sites, good clinical practice training was 
provided to at least two members of staff from the selected MDR-/
XDR-TB facilities. Strict adherence to the guidance document was 
stressed as the newer sites were not all experienced in conducting 
research. Once trained, the TB directorate of the NDoH set up an 
official start-up meeting at each of the sites. 
Protection of patients
The principle underpinning protection of participating patients 
is their ability and capacity to make autonomous decisions and to 
give informed consent. Both the CAP and the informed consent 
document were approved by each site’s research ethics committee 
prior to the start of the programme and enrolment of participants. 
A potential safety risk identified in the development of bedaquiline, 
in common with moxifloxacin and clofazimine that are included in 
MDR-TB treatment regimens, was the prolongation of the QTc 
interval on electrocardiogram (ECG) with associated risks of life-
threatening ventricular arrhythmias and sudden death. Thus, built 
into the CAP is rigorous ECG monitoring with only sites capable of 
adhering to this being permitted to enrol patients. 
Regulatory guidance
Clinical research sites that were involved in the phase 2 clinical trials 
of bedaquiline were approached first to implement a compassionate 
use programme for bedaquiline. A requirement to participate was that 
the patients who accessed the drug were treated within the national 
TB programme, thus ensuring that the new drug is supported by 
other quality assured and approved second-line TB drugs. 
In November 2011, the compassionate use programme was 
presented to the MCC by the MDR-TB directorate of the NDoH. The 
MCC was concerned at that time that the drug was not registered by 
any other regulatory authorities. They requested that the protocol 
be amended and implemented as a clinical trial, with appropriate 
safety monitoring, and with the TB directorate of the NDoH being 
responsible for sponsorship.
In collaboration with Right to Care and MSF, a CAP for SA was 
drafted by the NDoH based on the compassionate use framework. In 
December 2012, the CAP was approved by the MCC. 
Minimise the risk of treatment failure
Bedaquiline is a new TB drug with a novel mode of action. The old 
adage of never adding a single drug to a failing regimen is important 
to reduce the risk of developing acquired resistance. An SA clinical 
advisory committee was therefore established, comprising a number 
of experts in the treatment of MDR-/XDR-TB. This virtual committee 
operates by e-mail consensus, with all new cases being discussed, 
and three members, other than the proposing responsible clinician, 
approving the use of bedaquiline as part of an appropriate regimen. 
Regimens for individual patients accessing bedaquiline through the 
programme are individualised and tailored according to the patient’s 
TB susceptibility pattern, treatment history and exposure to other TB 
drugs, and other individual factors. Key roles of the committee are to 
ensure that bedaquiline is used only when other TB drugs known to 
be effective, or are likely to be effective, are available to be used in the 
patient’s regimen. The committee advises on an optimal treatment 
regimen for each case. 
Once approval from the local team is obtained, the responsible 
physician submits a patient summary to the Janssen Global 
Programme Manager who then co-ordinates clinical approval by 
Janssen, at the hands of a panel of clinical experts, and communicates 
the decision back to the responsible physician for each site. In 
parallel, approval is obtained from the MCC on a Section 21 or 
named-patient basis. 
Discussion
This initiative has had a number of far-reaching consequences. 
Firstly, patients with DR-TB that has a poor prognosis are being 
Table 1. MDR-TB patients, 2004 - 2010* 
Province
Patients, n
2004 2005 2006 2007 2008 2009 2010 2011 2012 Total, N
Eastern Cape 379 545 836 1 092 1 501 1 858 1 782 2 178 2 205 12 376
Free State 116 151 198 179 381 253 267 412 390 2 347
Gauteng 537 676 732 986 1 028 1 307 934 1 643 1 198 9 041
KwaZulu-Natal 583 1 024 2 200 2 208 1 573 1 773 2 032 1 825 6 630 19 848
Limpopo 59 40 77 91 185 204 126 290 266 1 338
Mpumalanga 162 134 139 506 657 446 312 824 760 3 940
Northern Cape 168 155 188 199 290 631 353 427 373 2 784
North West 130 203 225 397 363 520 158 473 267 2 736
Western Cape 1 085 1 192 1 179 1 771 2 220 2 078 1 422 2 013 2 072 15 032
Total, N 3 219 4 120 5 774 7 429 8 198 9 070 7 386 10 085 14 161 69 442
MDR-TB = multidrug-resistant tuberculosis.
*Laboratory diagnosis from the National Health Laboratory Service.
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offered expedited access to a novel drug in a safe and controlled 
environment. Secondly, the model that has been established may 
prove useful in the future for other new TB agents.
While much public attention has been paid to MDR-TB in the last 
5 years, it remains under-researched. The programme has expanded 
the capacity for research that does not exist currently in most MDR-
TB facilities. 
It bears noting that evidence for the regimen used in the current 
national TB treatment programme is based on expert opinion 
and not on clinical trial data. Cohort data from Van Deun et al.[5] 
demonstrated the efficacy of a seven-drug combination, 9-month 
course of treatment for MDR-TB. This so called ‘Bangladesh’ regimen 
consists of high-dose isoniazid, high-dose gatifloxacin, kanamycin, 
prothionamide, ethambutol, pyrazinamide and clofazimine given 
for only 9 months and is now being compared with the standard 18 
- 24-month regimen in The Evaluation of a Standardised Treatment 
Regimen of Anti-Tuberculosis Drugs for Patients with Multidrug-
Resistant Tuberculosis (STREAM), an International Union Against 
Tuberculosis and Lung Disease sponsored, non-inferiority clinical 
trial. This is the first of a number of trials aimed at establishing more 
effective, safer and shorter MDR-TB regimens using newly available 
drugs. The CAP in SA has provided the initial training and back-up 
for such clinical trials in the future. 
Finally, HIV co-infection with TB is very common in SA. National 
HIV guidelines mandate the expedited initiation of antiretroviral 
therapy in any patient with MDR-/XDR-TB. Data on concomitant 
antiretroviral use with bedaquiline will emerge following imple-
menation of the programme. 
Conclusion
There remains much work to be done to find a new effective, safe and 
evidence-based treatment regimen for MDR-/XDR-TB. Bedaquiline 
must form part of a long-term strategy aimed at combatting DR-TB. 
Other drugs that might include linezolid – an oxazalidinone that is 
also used for the treatment of resistant Gram-positive infections – 
and clofazimine – a drug used for the treatment of leprosy – must be 
added to develop regimens for the treatment of XDR- and pre-XDR-
TB. The CAP in SA has resulted in both access to treatment with a 
novel drug for patients with DR-TB and enhancement of research 
capacity.
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